The overall goal of this proposal is to develop integrated mathematical algorithms to assess the similarity of analytical characterization data comparing multiple batches of two different complex molecules. First, multiple batches of a biopolymer-drug conjugate (hyaluronic acid-cisplatin) and a pharmaceutically relevant glycoprotein (IgG1-Fc) will be prepared. For the IgG1-Fc molecules, we utilize technology to produce six different, well- defined glycoforms, which can be characterized individually and then mixed together in different ratios resulting in varying levels of binding activity to various Fc receptors for subsequent analytical comparability testing. Second, the biological, chemical and physical properties of both complex molecules will be monitored using a wide range of analytical technologies, including during accelerated stability testing to elucidate correlations between physicochemical changes and biological activity. Third, we will then employ a combination of currently available data visualization tools used our laboratories, along with novel mathematical algorithms to be developed in this proposal, to integrate the structural and biological data to provide an overall assessment of their critical quality attributes (CQAs). Finally, the ability of the mathematical algorithm(s) to assess the overall similarity of multiple lots of each complex biopharmaceutical will be validated using appropriate positive and negative controls, and therefore, provide an overall assessment of analytical comparability.

Public Health Relevance

This proposal will develop, implement and validate integrated mathematical algorithms to assess the similarity of multiple batches of two different complex molecules (a biopolymer mixture and IgG-based glycoproteins) using analytical comparability data sets from characterization (biological, chemical and physical) methods.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01FD005285-02
Application #
8925802
Study Section
Special Emphasis Panel (ZFD1)
Project Start
2014-09-10
Project End
2017-08-31
Budget Start
2015-09-01
Budget End
2016-08-31
Support Year
2
Fiscal Year
2015
Total Cost
Indirect Cost
Name
University of Kansas Lawrence
Department
Type
DUNS #
076248616
City
Lawrence
State
KS
Country
United States
Zip Code
66045
More, Apurva S; Toth 4th, Ronald T; Okbazghi, Solomon Z et al. (2018) Impact of Glycosylation on the Local Backbone Flexibility of Well-Defined IgG1-Fc Glycoforms Using Hydrogen Exchange-Mass Spectrometry. J Pharm Sci 107:2315-2324
Kleindl, Peter A; Xiong, Jian; Hewarathna, Asha et al. (2017) The Botanical Drug Substance Crofelemer as a Model System for Comparative Characterization of Complex Mixture Drugs. J Pharm Sci 106:3242-3256
Hewarathna, Asha; Mozziconacci, Olivier; Nariya, Maulik K et al. (2017) Chemical Stability of the Botanical Drug Substance Crofelemer: A Model System for Comparative Characterization of Complex Mixture Drugs. J Pharm Sci 106:3257-3269
Nariya, Maulik K; Kim, Jae Hyun; Xiong, Jian et al. (2017) Comparative Characterization of Crofelemer Samples Using Data Mining and Machine Learning Approaches With Analytical Stability Data Sets. J Pharm Sci 106:3270-3279
Mozziconacci, Olivier; Okbazghi, Solomon; More, Apurva S et al. (2016) Comparative Evaluation of the Chemical Stability of 4 Well-Defined Immunoglobulin G1-Fc Glycoforms. J Pharm Sci 105:575-587
More, Apurva S; Toprani, Vishal M; Okbazghi, Solomon Z et al. (2016) Correlating the Impact of Well-Defined Oligosaccharide Structures on Physical Stability Profiles of IgG1-Fc Glycoforms. J Pharm Sci 105:588-601
Okbazghi, Solomon Z; More, Apurva S; White, Derek R et al. (2016) Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis. J Pharm Sci 105:559-574
Kim, Jae Hyun; Joshi, Sangeeta B; Tolbert, Thomas J et al. (2016) Biosimilarity Assessments of Model IgG1-Fc Glycoforms Using a Machine Learning Approach. J Pharm Sci 105:602-612